Objective:To compare the efficacy of platinum-and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer(TNBC)and analyze the relationship between their efficacy and BRCA gene s...Objective:To compare the efficacy of platinum-and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer(TNBC)and analyze the relationship between their efficacy and BRCA gene status.Methods:Retrospectively analyze clinical data of 220 patients diagnosed pathologically with advanced TNBC and treated at the Department of Breast Oncology,Peking University Cancer Hospital from 2013 to 2018 and evaluate the efficacy of chemotherapy.A total of 114 patients had BRCA1/2 gene tested by next generation sequencing(NGS)using peripheral blood,and we analyzed the correlation between their efficacy and BRCA1/2 gene status.Results:Non-platinum-based chemotherapy(NPCT)was administered to 129 and platinum-based chemotherapy(PBCT)to 91 study patients.The clinical benefit rate(CBR)and median progression-free survival(PFS)were not statistically different between NPCT and PBCT groups.The median overall survival(OS)was 30.0 and 22.5 months for PBCT and NPCT group,respectively[P=0.090,hazard ratios(HR)=0.703].BRCA status was assessed in 114 patients,14 of whom had deleterious germline BRCA1/2(g BRCA)mutations(seven in each group).In PBCT group,the CBR was 85.7%and 35.1%for patients with and without deleterious g BRCA mutations,respectively(P=0.039).The median PFS were 14.9 and 5.3 months and median OS were 26.5 and 15.5 months for patients with and without deleterious g BRCA mutations,respectively(P=0.001,P=0.161,respectively).Patients in PBCT group had significantly greater rates of grade 3-4 anemia(5.5%vs.0%)and thrombocytopenia(8.8%vs.0%),whereas palmar-plantar erythrodysesthesia(12.4%vs.0%)and peripheral neuropathy(8.6%vs.1.1%)occurred more frequently in NPCT group.Conclusions:Platinum-based regimens are more effective in patients with deleterious g BRCA mutations,but no difference in patients without BRCA gene mutations,so non-platinum is an option in patients without BRCA gene mutations considering the toxicity and side effect.And we recommend that patients with advanced TNBC should have BR展开更多
Magnetically recyclable Au/Co/Fe core-shell nanoparticles （NPs） have been successfully synthesized via a one-step in situ procedure. Transmission electron microscope （TEM）, energy dispersive X-ray spectroscopic （...Magnetically recyclable Au/Co/Fe core-shell nanoparticles （NPs） have been successfully synthesized via a one-step in situ procedure. Transmission electron microscope （TEM）, energy dispersive X-ray spectroscopic （EDS）, and electron energy-loss spectroscopic （EELS） measurements revealed that the trimetallic Au/Co/Fe NPs have a triple-layered core-shell structure composed of a Au core, a Co-rich inter-layer, and a Fe-rich shell. The Au/Co/Fe core-shell NPs exhibit much higher catalytic activities for hydrolytic dehydrogenation of ammonia borane （NHBBH3, AB） than the monometallic （Au, Co, Fe） or bimetallic （AuCo, AuFe, CoFe） counterparts.展开更多
A group G is said to be(2,3,t) -generated if it can be generated by an involution x and an element y so that 0(y)=3?and 0(xy)=t. In the present article, we determine all (2,3,t)-generations for the Rudvalis sporadic s...A group G is said to be(2,3,t) -generated if it can be generated by an involution x and an element y so that 0(y)=3?and 0(xy)=t. In the present article, we determine all (2,3,t)-generations for the Rudvalis sporadic simple group Ru, where t is any divisor of .展开更多
Aim:Triple negative breast cancer(TNBC)is known as aggressive subtype and have no identified targeted therapies.We examined the relationship of neoadjuvant chemotherapy response to genetic variations of TNBC.Methods:T...Aim:Triple negative breast cancer(TNBC)is known as aggressive subtype and have no identified targeted therapies.We examined the relationship of neoadjuvant chemotherapy response to genetic variations of TNBC.Methods:The tumors used in this study were collected from Showa University Hospital,Japan.Thirteen formalin-fixed paraffin-embedded tumors from Japanese TNBC patients who underwent neoadjuvant chemotherapy were used for analysis.Of these,eight surgically resected tumors showed progressive disease and/or recurrence after treatment(PD/REC),and biopsy tissues from five patients showing pathological complete response(pCR)were analyzed.DNA extracted from tissue sample were analyzed.The Miseq system and Trusight Tumor Sequence panel kit were used to sequence 174 amplicons over 82 exons of 26 cancer-related genes to identify genetic mutations.Results:Seven somatic non-synonymous variants were detected in three genes(FOXL2,PIK3CA,and TP53)in all five pCR patients,and six somatic non-synonymous variants in two genes(PTEN and TP53)were detected in six of eight PD/REC patients.Eight of 13 TNBC tumors were found to have TP53 pathogenic variants,in both pCR and PD/REC cases.Conclusion:Although TP53 variation was detected in both pCR and PD/REC cases,each location and type of the variant were different.We could not identify genetic mutations associated with chemotherapy response and recurrence.展开更多
文摘Objective:To compare the efficacy of platinum-and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer(TNBC)and analyze the relationship between their efficacy and BRCA gene status.Methods:Retrospectively analyze clinical data of 220 patients diagnosed pathologically with advanced TNBC and treated at the Department of Breast Oncology,Peking University Cancer Hospital from 2013 to 2018 and evaluate the efficacy of chemotherapy.A total of 114 patients had BRCA1/2 gene tested by next generation sequencing(NGS)using peripheral blood,and we analyzed the correlation between their efficacy and BRCA1/2 gene status.Results:Non-platinum-based chemotherapy(NPCT)was administered to 129 and platinum-based chemotherapy(PBCT)to 91 study patients.The clinical benefit rate(CBR)and median progression-free survival(PFS)were not statistically different between NPCT and PBCT groups.The median overall survival(OS)was 30.0 and 22.5 months for PBCT and NPCT group,respectively[P=0.090,hazard ratios(HR)=0.703].BRCA status was assessed in 114 patients,14 of whom had deleterious germline BRCA1/2(g BRCA)mutations(seven in each group).In PBCT group,the CBR was 85.7%and 35.1%for patients with and without deleterious g BRCA mutations,respectively(P=0.039).The median PFS were 14.9 and 5.3 months and median OS were 26.5 and 15.5 months for patients with and without deleterious g BRCA mutations,respectively(P=0.001,P=0.161,respectively).Patients in PBCT group had significantly greater rates of grade 3-4 anemia(5.5%vs.0%)and thrombocytopenia(8.8%vs.0%),whereas palmar-plantar erythrodysesthesia(12.4%vs.0%)and peripheral neuropathy(8.6%vs.1.1%)occurred more frequently in NPCT group.Conclusions:Platinum-based regimens are more effective in patients with deleterious g BRCA mutations,but no difference in patients without BRCA gene mutations,so non-platinum is an option in patients without BRCA gene mutations considering the toxicity and side effect.And we recommend that patients with advanced TNBC should have BR
文摘Magnetically recyclable Au/Co/Fe core-shell nanoparticles （NPs） have been successfully synthesized via a one-step in situ procedure. Transmission electron microscope （TEM）, energy dispersive X-ray spectroscopic （EDS）, and electron energy-loss spectroscopic （EELS） measurements revealed that the trimetallic Au/Co/Fe NPs have a triple-layered core-shell structure composed of a Au core, a Co-rich inter-layer, and a Fe-rich shell. The Au/Co/Fe core-shell NPs exhibit much higher catalytic activities for hydrolytic dehydrogenation of ammonia borane （NHBBH3, AB） than the monometallic （Au, Co, Fe） or bimetallic （AuCo, AuFe, CoFe） counterparts.
文摘A group G is said to be(2,3,t) -generated if it can be generated by an involution x and an element y so that 0(y)=3?and 0(xy)=t. In the present article, we determine all (2,3,t)-generations for the Rudvalis sporadic simple group Ru, where t is any divisor of .
基金This work was supported in part by a Grant-in-Aid for the High-Technology Research Center Project from the Ministry of Education,Culture,Sports,Science and Technology of Japan.
文摘Aim:Triple negative breast cancer(TNBC)is known as aggressive subtype and have no identified targeted therapies.We examined the relationship of neoadjuvant chemotherapy response to genetic variations of TNBC.Methods:The tumors used in this study were collected from Showa University Hospital,Japan.Thirteen formalin-fixed paraffin-embedded tumors from Japanese TNBC patients who underwent neoadjuvant chemotherapy were used for analysis.Of these,eight surgically resected tumors showed progressive disease and/or recurrence after treatment(PD/REC),and biopsy tissues from five patients showing pathological complete response(pCR)were analyzed.DNA extracted from tissue sample were analyzed.The Miseq system and Trusight Tumor Sequence panel kit were used to sequence 174 amplicons over 82 exons of 26 cancer-related genes to identify genetic mutations.Results:Seven somatic non-synonymous variants were detected in three genes(FOXL2,PIK3CA,and TP53)in all five pCR patients,and six somatic non-synonymous variants in two genes(PTEN and TP53)were detected in six of eight PD/REC patients.Eight of 13 TNBC tumors were found to have TP53 pathogenic variants,in both pCR and PD/REC cases.Conclusion:Although TP53 variation was detected in both pCR and PD/REC cases,each location and type of the variant were different.We could not identify genetic mutations associated with chemotherapy response and recurrence.
